TNFSF4 and lymphoma: In this regard, currently, there are two ongoing phase I clinical trials about the use of mRNA-loaded LNPs that encode OX40L (mRNA-2416, NCT03323398) or OX40L/IL-23/IL-36γ (mRNA-2752, NCT03739931), alone or in combination with the anti-PD-L1 durvalumab, for the treatment of lymphoma [41, 42].